Project: Development of Novel Targeted Drugs for Treatment of Liver Fibrosis
| Acronym | DeFiber (Reference Number: 12350) |
| Duration | 01/10/2018 |
| Project Topic | The aim is to develop the first targeted treatment for patients suffering from liver fibrosis (LF). The approach is based on a nanobody-drug-conjugate (NDC), targeted to hepatic stellate cells (HSC), by linking HSC-specific nanobodies to a fibrotic scar diminishing drug, using the proprietary Lx-linker, together called LxL-LF. DeFiber aims to select the best LxL-LF candidate based on in vitro and in vivo studies, and to develop complementary diagnostics, preparing for the (pre-)clinical phases. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 9 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | LinXis Pharmaceuticals B.V. | Coordinator | Netherlands |
| 2 | ChemCon GmbH | Partner | Germany |
| 3 | Universitatsklinikum Bonn | Partner | Germany |